汇宇制药：2025年前三季度净利润约-5080万元

Group 1 - The core viewpoint of the news is that Huiyu Pharmaceutical reported a decline in revenue and a net loss for the third quarter of 2025, indicating financial challenges for the company [1] - For the first three quarters of 2025, the company's revenue was approximately 742 million yuan, representing a year-on-year decrease of 12.92% [1] - The net profit attributable to shareholders was a loss of approximately 50.8 million yuan, with basic earnings per share showing a loss of 0.12 yuan [1] Group 2 - As of the report, Huiyu Pharmaceutical's market capitalization stands at 8.7 billion yuan [2] - The broader market context indicates that the A-share market has surpassed 4000 points, marking a significant recovery and a new "slow bull" market pattern [2]